Kura Oncology Inc at Citi Biotech Conference Transcript
Session 2, focusing the laser on precision oncology. We had some companies yesterday on this theme, so this is our sequel. So it's my pleasure to introduce the Chief Executive Officers of Epizyme, Robert Bazemore; sitting over in the middle, from Kura, Troy Wilson, President and CEO; and to my right, Ali Tehrani, the CEO of Zymeworks.
So welcome all of you, thanks for taking the time. And just to start out, I think it would be helpful if each of you could give a quick 2- to 3-minute overview of your pipeline, your strategy, what are the key objectives for each of your companies.
Ali, you want to kick it off?
Sure. Thank you very much for organizing this conference and having us here. Zymeworks has focused on the research and development of multifunctional biologics. Currently, we have a number of bispecific antibodies in the clinic, our lead product is ZW25, which is a biparatopic antibody focused on HER2
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |